Abstract 963P
Background
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Early detection of HCC is critical for timely treatment and a better prognosis. In this prospective study (ASCEND-Hep, NCT04835675), we aimed to explore multi-omics including cell-free DNA (cfDNA) methylation, mutation, and α-fetoprotein (AFP) in early detection of HCC.
Methods
This multicenter study prospectively collected blood samples from patients with HCC and benign liver diseases. Age-matched non-cancer controls were obtained from a previous study. Methylation and mutation were detected through a methylation panel of 161,984 CpG sites and a cancer-associated 168-gene panel, respectively. Models were developed in a training set (cancer: 172; non-cancer: 206) and tested in a validation set (cancer: 117; non-cancer: 140). Then the locked models were validated in an independent validation set (cancer: 158; non-cancer: 637).
Results
In the training set, cfDNA methylation model had a higher area under curve than AFP and mutation alone (P<0.05). In the validation set, the methylation model yielded an overall sensitivity of 92.3% (95% CI, 85.9%–96.4%) at a specificity of 95.0% (90.0%–98.0%). Meanwhile, AFP >400 ng/mL had a sensitivity of 27.3% (18.8%–37.2%) with a specificity of 100.0% (96.5%–100.0%). Combining cfDNA methylation and AFP showed a better performance with a sensitivity of 94.0% (88.1%–97.6%) and a specificity of 95.0% (90.0%–98.0%), while the addition of mutation did not further improve the performance. Consistent results were observed in the independent validation set that the combined model achieved a sensitivity of 90.5% (84.8%–94.6%) at a specificity of 97.3% (95.8%–98.4%). The sensitivity of the combined model in Barcelona Clinic Liver Cancer Classification 0–A was 87.1% (78.0%–93.4%).
Conclusions
cfDNA methylation yielded superior performance than AFP and mutation alone. Our study highlights a potential clinical utility of combining cfDNA methylation and AFP for HCC early detection.
Clinical trial identification
NCT04835675.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Burning Rock Bioengineering Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
946P - Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
Presenter: Shichun Lu
Session: Poster session 18
947P - The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma: A phase Ib/II clinical trial
Presenter: Li Bai
Session: Poster session 18
949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study
Presenter: Bin-Kui Li
Session: Poster session 18
952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): A multicenter, single-armed, real-world study
Presenter: Guoliang Shao
Session: Poster session 18
953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial
Presenter: Zhongchao Li
Session: Poster session 18
954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: A single arm, phase II clinical trial
Presenter: Guishu wu
Session: Poster session 18
955P - IMMUNIB trial (AIO-HEP-0218/ass): A single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced hepatocellular carcinoma
Presenter: Arndt Vogel
Session: Poster session 18